EmbraceRX review

EmbraceRX shows sixteen longevity options and public prices, including sermorelin injection at $137.70 a month and NAD⁺ nasal spray at $93.15 a month. That makes the core shelf easier to compare. Several listed items cannot yet be ordered online, the NAD⁺ routes have different state exclusions, and the price on a product card does not settle your prescribed quantity or renewal terms. The prescribing network is named, but the dispensing pharmacy is not.

EmbraceRX, trading as Embrace Rx, is a telehealth commerce platform with independent licensed physician networks, including Samaritan MD; its FAQ also names Prescribery Health as a virtual-care partner. The public longevity shelf currently lists sixteen options: injections, capsules, topicals and nasal sprays. It includes sermorelin, CJC-1295/ipamorelin, thymosin, GHK-Cu, glutathione and NAD⁺. A separate questionnaire offers access to more treatments, but it does not establish what is currently available to every patient. Some public cards, including sermorelin/ipamorelin, oral glutathione and several topical products, say they cannot yet be ordered online. The site displays a linked LegitScript badge and publishes terms, privacy, HIPAA and refund notices.

You can browse prices before starting an order. A clinician selects the strength after the visit; the FAQ says refills involve provider review and a monthly payment choice rather than an automatic debit. The FAQ also says an order cannot be changed or canceled once placed, while the returns policy allows subscription cancellation before shipping and makes prescription sales final once charged and handed to the carrier. Those statements distinguish an individual order from future refills but leave any pre-shipment refund uncertain. One FAQ says billing occurs when medicine ships, while sermorelin capsules advertise a charge today. Ask which applies to your selected product. The platform names physician partners but no dispensing pharmacy; state access depends on the product.

The public shelf lists sermorelin injection at $137.70 a month, capsules from $93.69 to $209.52 by strength, and CJC-1295/ipamorelin injection at $162. NAD⁺ nasal spray is $93.15 a month, injectable solution $136.35 and capsules $157.40; the capsule description calls it a precursor without identifying NR or NMN. GHK-Cu capsules are $130.67 and cream $133.11; glutathione nasal spray is $117.90. Some other cards show prices but say they cannot yet be ordered online. These are advertised monthly figures, not a verified first debit, dispensed supply or renewal contract. The separate GLP-1 special from $81 a month and three-month TRT promotion are not peptide or NAD⁺ rates.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. EmbraceRX says its prescriptions are filled by 503A patient-specific compounding programs at state-licensed pharmacies but names none, and compounded sterile products are not reviewed by FDA for purity and potency the way approved drugs are. A broad private treatment questionnaire does not establish public availability of every compound. BPC-157, absent from the current public shelf, has essentially no controlled human outcome trials; its healing reputation comes from animal work and user reports. It was on FDA's Category 2 compounding list until April 2026 and is not yet cleared for pharmacy compounding — a July 2026 advisory vote to add it to the 503A bulks list is non-binding — so confirm what can actually be dispensed to you now. GHK-Cu and nasal glutathione likewise have no controlled human outcome evidence for the skin, recovery and detoxification claims attached to them. NAD⁺ by nasal spray has no controlled outcome trials either; the studied forms are the oral precursors NR and NMN, which raise blood NAD⁺ without demonstrating a clinical benefit. Sermorelin and CJC-1295/ipamorelin act on a real growth-hormone axis but with thin long-term outcome data. MOTS-C, epithalon, SS-31 and LL-37 are further out still, and neither Melanotan II nor SLU-PP-332, neither on the public shelf, is an FDA-approved drug. Individual results vary.